Generic Name: Generic anafranil
What is Generic Anafranil?
Anafranil clomipramine is an antidepressant with sedative and mild analgesic effect. The active substance of Anafranil is clomipramine. The main Anafranil clomipramine indications include: anxiety and depressive disorders, depressive syndrome in schizophrenia, personality disorders, depressive states provoked by chronic pain, panic attacks. Anafranil is effective for chronic pain in cancer patients, patients suffering from migraines, headaches, rheumatism, postherpetic neuralgia, peripheral neuropathy, narcolepsy, and catalepsy.
Moreover, clomipramine helps reduce appetite and fight involuntary leakage of urine which is not associated with urinary tract disorders. Anafranil tablets can be taken after meals or with food. Usually, the entire daily dose is taken at one time, before going to bed. Treatment of phobias, depression, obsessive-compulsive disorder: take Anafranil 2-3 times a day at a dose of 25 mg.
During the first week the daily dosage may be gradually increased to 100-150 mg. The maintenance dose is 50-100 mg per day. Once the desired effect is reached, the therapy is continued for several days.
Of the 196 adolescents studied, 50 were 13 years of age or less and 146 were 14 to 17 years of age. The adverse reaction profile in this age group see ADVERSE REACTIONS is similar to that observed in adults. The risks, if any, that may be associated with Anafranil's extended use in children and adolescents with OCD have not been systematically assessed. The evidence supporting the conclusion that Anafranil is safe for use in children and adolescents is derived from relatively short term clinical studies and from extrapolation of experience gained with adult patients.
In particular, there are no studies that directly evaluate the effects of long term Anafranil use on the growth, development, and maturation of children and adolescents.
Although there is no evidence to suggest that Anafranil adversely affects growth, development or maturation, the absence of such findings is not adequate to rule out a potential for such effects in chronic use. The safety and effectiveness in pediatric patients below the age of 10 have not been established.
Therefore, specific recommendations cannot be made for the use of Anafranil in pediatric patients under the age of 10. No unusual age-related adverse events were identified in this population. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. Deaths may occur from overdosage with this class of drugs.
Multiple drug ingestion including alcohol is common in deliberate tricyclic overdose.
How should I take Generic Anafranil?
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. While all the selective serotonin reuptake inhibitors SSRIse. Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCA metabolism.
Concomitant use of agents in the tricyclic antidepressant class which includes Anafranil with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug. Furthermore, whenever one of these drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant agent may be required.
What should I avoid while taking Generic Anafranil?
This fact must be considered in assessing the estimates of the pharmacokinetic parameters presented below, as these were obtained in individuals exposed to doses of 150 mg. If the pharmacokinetics of CMI and DMI are nonlinear at doses above 150 mg, their elimination half-lives may be considerably lengthened at doses near the upper end of the recommended dosing range i. Consequently, CMI and DMI may accumulate, and this accumulation may increase the incidence of any dose- or plasma-concentration-dependent adverse reactions, in particular seizures see WARNINGS.
After a 150 mg dose, the half-life of CMI ranges from 19 hours to 37 hours mean, 32 hr and that of DMI ranges from 54 hours to 77 hours mean, 69 hr. Steady-state levels after multiple dosing are typically reached within 7 to 14 days for CMI. Plasma concentrations of the metabolite exceed the parent drug on multiple dosing.
Generic Anafranil side effects
Anafranil may create new or exacerbate existing psychosis, delusions, and paranoia. Call your doctor immediately if you or your child experiences new or worsening mental health symptoms including hallucinations or confusion. This drug may trigger a psychotic episode for patients with previously undiagnosed schizophrenia. Treatment with Anafranil can increase the risk of simultaneous treatment for depression with electroconvulsive therapy.
Talk with your doctor about any liver function problems or blood conditions.
Common Generic Anafranil ide effects may include:
Call your doctor immediately if you or your child experiences new or worsening mental health symptoms including hallucinations or confusion.
The goal of this initial titration phase is to minimize side effects by permitting tolerance to side effects to develop or allowing the patient time to adapt if tolerance does not develop.
Side effects can be mild or severe, temporary or permanent.
Since clomipramine may diminish or abolish the antihypertensive effects of guanethidine, clonidine, reserpine, methyldopa, patients requiring concomitant treatment for hypertension should be given antihypertensives of a different type e.
Withdrawal Symptoms A variety of withdrawal symptoms have been reported in association with abrupt discontinuation of Anafranil, including dizziness, nausea, vomiting, headache, malaise, sleep disturbance, hyperthermia, and irritability.
Information For Patients Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with clomipramine hydrochloride and should counsel them in its appropriate use.
Clinical Worsening And Suicide Risk Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia psychomotor restlessnesshypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down.
Patients should be advised that taking Anafranil can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure glaucoma.
Where can I get more information?
However, similar to other TCAs, clomipramine is thought to enhance the actions of norepinephrine and serotonin chemical neurotransmitters in the brain that nerves use to communicate with one another by blocking their reuptake and prolonging their activity.
Clomipramine passes into maternal milk in concentrations similar to those in plasma and crosses the placenta.